Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease.
Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease.
复制标题
人类免疫缺陷病毒感染后免疫异常的非随机发展：对该疾病免疫学分类的影响。
DOI：
10.1073/pnas.84.15.5404
复制
发表时间：
1987
影响因子：
11.1
通讯作者：
Garber,J
中科院分区：
文献类型：
--
作者：
Zolla-Pazner,S;DesJarlais,DC;Friedman,SR;Spira,TJ;Marmor,M;Holzman,R;Mildvan,D;Yancovitz,S;Mathur-Wagh,U;Garber,J
从165静脉吸毒者血清阳性的人免疫缺陷病毒（HIV），从158血清阳性的同性恋男子淋巴结病，并从77例获得性免疫缺陷综合征（AIDS）的血液标本进行了免疫学评估。通过Guttman量表技术分析免疫学参数，以确定免疫学异常是否以非随机模式发生。出现了以下四种模式：（i）HIV血清阳性，无免疫学异常;（ii）HIV血清阳性，T4/T8细胞比率降低;（iii）血清阳性，T4/T8细胞比率降低和T4细胞耗竭;（iv）血清阳性，T4/T8细胞比率降低，T4细胞耗竭和淋巴细胞减少。发现三组患者中的每一组中92%至100%的受试者“符合比例”，因为异常以所述的累积、有序方式发生。这种异常的非随机发生表明HIV感染者免疫异常的有序进展，这一发现有助于对有症状和无症状的HIV血清阳性受试者进行分期。
Blood specimens from 165 intravenous drug users who were seropositive for the human immunodeficiency virus (HIV), from 158 seropositive homosexual men with lymphadenopathy, and from 77 patients with acquired immunodeficiency syndrome (AIDS) were assessed immunologically. Immunologic parameters were analyzed by the Guttman scalogram technique to determine if immunologic abnormalities occurred in a nonrandom pattern. The following four patterns emerged: (i) seropositivity for HIV with no immunologic abnormalities; (ii) seropositivity for HIV with a depressed T4/T8 cell ratio; (iii) seropositivity with a depressed T4/T8 cell ratio and T4-cell depletion; and (iv) seropositivity with a depressed T4/T8 cell ratio, T4-cell depletion, and lymphopenia. Ninety-two to 100% of subjects in each of the three groups of patients were found "to scale" because the abnormalities occurred in the cumulative, ordered fashion described. This nonrandom occurrence of abnormalities indicates an ordered progression of immunologic abnormalities in individuals infected with HIV, a finding useful in the staging of both symptomatic and asymptomatic HIV-seropositive subjects.